$2.1m Novartis gene therapy to become world's most expensive drug
US approves the one-time treatment for deadly spinal muscular atrophy in infantsSwiss drugmaker Novartis has received US approval for its spinal muscular atrophy gene therapy Zolgensma – pricing the one-time treatment at a record $2.125m.The Food and Drug Administration on Friday approved Zolgensma for children under the age of two Read more

